Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of GSK5926371 in relapsed or refractory B-cell non-Hodgkin lymphoma
2025-524915-36-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of GSK5926371 in mature B-cell lymphoma, sponsored by GSK. Primary endpoints: Dose-limiting toxicities and Adverse events and serious adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
GSK5926371
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2025-524915-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524915-36-00.